Drug Trial Radar · NCT05555732
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,233
Actual
Start
Jan 11, 2023
Primary completion
May 11, 2029
Study completion May 11, 2031
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca; Merck Sharp & Dohme LLC
- First posted
- Sep 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Conditions
- Metastatic Non Small Cell Lung Cancer
Interventions
Datopotamab DeruxtecanDrug
Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
PembrolizumabDrug
Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
PemetrexedDrug
Pemetrexed will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
CarboplatinDrug
Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
CisplatinDrug
Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival Based on Blinded Independent Central Review in All Randomized ParticipantsTime frame: From randomization until disease progression or death (whichever occurs first), up to approximately 43 months
- Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants who are TROP2 NMR positiveTime frame: From randomization until disease progression or death (whichever occurs first), up to approximately 43 months
- Overall Survival in All Randomized ParticipantsTime frame: From randomization until disease progression or death (whichever occurs first), up to approximately 76 months
- Overall Survival in All Randomized Participants who are TROP2 NMR positiveTime frame: From randomization until disease progression or death (whichever occurs first), up to approximately 76 months
Locations
260 sites in 29 countries. Site status is shown where the registry gives one.
Southern Cancer Center Pc
Daphne, Alabama
Ironwood Cancer and Research Centers
Chandler, Arizona
Arizona Oncology Associates, Pc - Nahoa
Prescott Valley, Arizona
Hoag Memorial Hospital Prebyterian
Newport Beach, California
Compassionate Cancer Care Medical Group
Riverside, California
Sansum Clinic
Santa Barbara, California
Ronald Reagan UCLA Medical Center
Santa Monica, California
UCHealth Memorial Hospital
Colorado Springs, Colorado
Florida Cancer Specialists - South
Fort Myers, Florida
Cancer Specialist of North Florida
Jacksonville, Florida
Cancer Care Centers of Brevard, Inc.
Palm Bay, Florida
Woodlands Medical Specialists, Pa
Pensacola, Florida
Florida Cancer Specialists-North
St. Petersburg, Florida
Emory University - Winship Cancer Institute Wci
Atlanta, Georgia
Illinois Cancer Specialists
Niles, Illinois
American Oncology Partners of Maryland
Bethesda, Maryland
Maryland Oncology Heamtology P.A.
Columbia, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute; Inv Drg Svc Pharm
Boston, Massachusetts
Dana Farber Cancer Institute At St. Elizabeth'S Medical Center
Brighton, Massachusetts
Dana Farber Brigham Cancer Center
Foxborough, Massachusetts
Dana Farber At Milford Regional Cancer Center
Milford, Massachusetts
Dana Farber/Bwcc in Affiliation With South Shore Hospital
South Weymouth, Massachusetts
Astera Cancer Care
East Brunswick, New Jersey
Regional Cancer Care Associates LLC
Hackensack, New Jersey
North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists- New Hyde Park
New Hyde Park, New York
North Shore Hematology Oncology Associates
Patchogue, New York
North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists
Port Jefferson Station, New York
North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists - Bronx
The Bronx, New York
Texas Oncology, P.A.
McAllen, Texas
Ut Health San Antonio
San Antonio, Texas
Texas Oncology, P.A.
Sugar Land, Texas
Texas Oncology-Tyler
Tyler, Texas
Utah Cancer Specialists IHO Corp
Salt Lake City, Utah
Providence Regional Cancer System
Lacey, Washington
VA Puget Sound Health Care System
Seattle, Washington
Centro de Investigaciones Medicas y Desarrollo LC SRL
Buenos Aires, Argentina
Instituto Alexander Fleming
Buenos Aires, Argentina
Fundacion CENIT para la investigacion en Neurociencias
Ciudad Autonoma de Buenos Aire, Argentina
Hospital de La Comunidad
Mar del Plata, Argentina
Showing 40 of 260 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.